Cholera Vaccine Development: Progress, Efficacy, and Public Health Strategies

The late 19th century marked the beginning of serious attempts to develop a cholera vaccine, coinciding with the establishment of the germ theory of disease. Russian scientist Waldemar Haffkine pioneered this field, creating one of the first cholera vaccines in the 1890s. Haffkine's vaccine was a killed, injectable formulation derived from heat-killed Vibrio cholerae bacteria. His self-experimentation and subsequent field trials in India during a cholera epidemic demonstrated some efficacy, but the vaccine faced several limitations. Notably, it provided only modest protection, with immunity waning quickly, often within months, and was associated with adverse reactions such as fever and pain at the injection site (Luquero et al., 2014; Ivers et al., 2013). These challenges highlighted the need for more effective and user-friendly vaccination strategies.

Throughout the 20th century, the development of cholera vaccines continued, but progress was slow and fraught with difficulties. The initial focus remained on injectable vaccines, which, while somewhat effective, were hampered by variability in efficacy across different populations and strains of Vibrio cholerae. Field trials revealed that the effectiveness of these vaccines could differ significantly based on local epidemiological conditions (Khuntia et al., 2021; Ilboudo & Gargasson, 2017). Moreover, cholera's persistence in water sources and its association with inadequate sanitation underscored the necessity for comprehensive public health measures beyond vaccination alone. The realization that vaccines could not single-handedly control cholera outbreaks led to a more integrated approach that combined vaccination with improved sanitation and water quality (Ivers et al., 2015; Martin et al., 2014).

The limitations of injectable vaccines paved the way for developing OCVs, representing a significant advancement in cholera prevention strategies. The transition to oral vaccines was driven by their ease of administration, particularly in resource-limited settings where healthcare infrastructure was lacking. Oral vaccines were designed to stimulate local immunity in the gastrointestinal tract, the primary site of infection for Vibrio cholerae (Martínez-Pino et al., 2013; Islam et al., 2018). The first-generation OCVs developed in the 1960s and 1970s included killed and live-attenuated formulations. While these vaccines demonstrated some protective efficacy, they still required multiple doses and often resulted in short-lived immunity (Ali et al., 2016; Mahalanabis et al., 2008).

The late 20th century saw the emergence of second-generation OCVs, which were more effective and safer than their predecessors. One of the most notable developments was the introduction of Dukoral in 1991, which combined killed whole cells of Vibrio cholerae with a component of cholera toxin. This innovative formulation enhanced the immune response, protecting the patient for up to two years with just two doses (Sayeed et al., 2015; Qadri et al., 2016). The World Health Organization (WHO) recognized the potential of OCVs and began to advocate for their use in cholera-endemic regions, particularly during outbreaks (Kar et al., 2014; Sow et al., 2017). The success of Dukoral set the stage for further advancements in OCV technology. In 2011, Shanchol was introduced as an improved and more affordable OCV. Unlike Dukoral, Shanchol did not require a buffer solution for administration, making it easier to deploy in mass vaccination campaigns. Shanchol is based on killed whole-cell Vibrio cholerae and has been shown to provide long-lasting immunity, with studies indicating protection lasting up to five years (Sarker et al., 2015; Sur et al., 2011). The vaccine has been utilized extensively in cholera-endemic countries and during outbreaks, such as the response to the cholera epidemic in Haiti following the 2010 earthquake (Kar et al., 2014; Ilboudo et al., 2021). The introduction of Shanchol marked a turning point in cholera vaccination efforts, as it allowed for broader access to effective vaccines in vulnerable populations. Euvichol, a variant of Shanchol, was developed to enhance the affordability and accessibility of OCVs further. Packaged in plastic containers instead of glass vials, Euvichol aimed to reduce costs and facilitate distribution in humanitarian crises and outbreak responses (Bekolo et al., 2016; Falkard et al., 2019). The WHO's establishment of a global stockpile of OCVs has also played a crucial role in ensuring that vaccines are available for rapid deployment in response to cholera outbreaks worldwide (Ivers et al., 2015; Poncin et al., 2017). This proactive approach to cholera vaccination has been instrumental in controlling the disease in various settings and has underscored the importance of vaccination as a public health tool.

Recent studies have demonstrated the effectiveness of OCVs in diverse populations, including those with specific vulnerabilities, such as individuals living with HIV. Research has shown that the immunogenicity of OCVs remains robust even in these populations, further supporting the use of cholera vaccination as a critical intervention (Ali et al., 2017; Charles et al., 2014). The ongoing evaluation of OCVs in various epidemiological contexts provides valuable insights into their effectiveness and safety, reinforcing the need for sustained investment in cholera vaccine research and deployment. Despite the progress made in cholera vaccine development, challenges remain. The need for continuous monitoring of vaccine efficacy, safety, and public acceptance is paramount, particularly in regions where cholera is endemic. Additionally, integrating vaccination campaigns with broader public health initiatives, including water and sanitation infrastructure improvements, is essential to achieve long-term cholera control (Hsiao et al., 2017). The lessons learned from past vaccination campaigns can inform future strategies, ensuring that cholera vaccination remains vital to global health efforts.

3. Current Cholera Vaccines

Cholera, an acute diarrheal disease caused by the bacterium Vibrio cholerae, remains a significant public health challenge, particularly in regions with inadequate sanitation and clean water access. Developing cholera vaccines has been a crucial strategy in controlling outbreaks and preventing the disease. Three primary OCV are widely used: Dukoral®, Shanchol®, and Euvichol®. Each of these vaccines has unique characteristics regarding their composition, administration, efficacy, and safety profiles (Table 2), which are critical for implementing public health strategies.

Integrating vaccination campaigns with WASH programmes can further enhance public health outcomes. Improved sanitation and hygiene practices reduce the transmission of infectious diseases and support the efficacy of vaccines by creating healthier environments for immunization. For example, vaccination and WASH initiatives effectively control cholera outbreaks, as evidenced by studies conducted in various settings (Parker et al., 2017). Furthermore, establishing robust surveillance systems is crucial for monitoring vaccination coverage and tracking outbreaks. This integration allows timely responses to emerging health threats, ensuring sustained community protection (Azman et al., 2012). Faucher et al. (2021) stress the importance of surveillance and note that effective monitoring can facilitate rapid vaccination responses in workplaces and schools during outbreaks.

Targeting high-risk populations and outbreak hotspots is not merely a logistical necessity but a moral imperative in public health. Vulnerable groups often bear the brunt of infectious disease outbreaks, and prioritizing their vaccination can significantly reduce morbidity and mortality rates. For instance, studies have shown that healthcare workers are at an increased risk of exposure to infectious diseases, making their vaccination a priority (Morrison et al., 2020). Similarly, the elderly and individuals with chronic health conditions are more susceptible to severe infection outcomes, underscoring the need for targeted vaccination strategies (Hall et al., 2017). Public health authorities can achieve excellent herd immunity and protect the broader community from outbreaks by focusing on these high-risk populations.

Moreover, the effectiveness of vaccination strategies can be enhanced through community engagement and education. Educating communities about the importance of vaccination and addressing vaccine hesitancy are critical components of successful vaccination campaigns. Research indicates that individual decision-making regarding vaccination can significantly influence outbreak dynamics, suggesting that targeted communication strategies can improve vaccination uptake (Morrison et al., 2020). Additionally, fostering trust in healthcare systems and ensuring equitable access to vaccines is essential for achieving high coverage rates among vulnerable populations (Parpia et al., 2020). This approach aligns with the findings of Parpia et al. (2020), who emphasized the need for comprehensive vaccination programmes that address access and education.

The integration of vaccination with WASH programmes also highlights the interconnectedness of public health strategies. Improved sanitation and hygiene practices can reduce the incidence of diseases that vaccines aim to prevent, thereby enhancing public health outcomes. For instance, cholera vaccination campaigns are more effective when combined with efforts to improve water quality and sanitation (Martin et al., 2014). This holistic approach addresses immediate health threats and contributes to long-term health improvements within communities. As noted by Gachohi et al., targeted interventions in identified hotspots can lead to sustainable disease elimination efforts, particularly when combined with education and community involvement (Gachohi et al., 2022).

Surveillance systems play a pivotal role in the success of vaccination campaigns, enabling health authorities to monitor vaccination coverage and assess the effectiveness of interventions. Effective surveillance can identify gaps in coverage and inform targeted vaccination efforts, particularly in areas with low uptake (Kundrick et al., 2018). For example, spatial clustering data can help identify high-risk areas for outbreaks, allowing for timely vaccination responses (Roskosky et al., 2020). This proactive approach is essential for controlling infectious diseases and preventing widespread outbreaks, as highlighted by the experiences documented in various studies (Merler et al., 2016). Integrating surveillance with vaccination efforts ensures that public health responses are data-driven and responsive to emerging threats. In addition to traditional vaccination strategies, innovative approaches such as reactive vaccination have gained traction recently. Reactive vaccination involves administering vaccines in response to an outbreak, targeting specific populations or areas to contain the spread of disease. This strategy has been successfully implemented in various contexts, including cholera and measles outbreaks, where rapid vaccination efforts have proven effective in controlling transmission (Alberti et al., 2010). The flexibility of reactive vaccination allows health authorities to respond swiftly to changing epidemiological landscapes, ensuring that resources are allocated where they are most needed (Faucher et al., 2022). This adaptability is crucial in evolving public health challenges, particularly in resource-limited settings.

Furthermore, the role of community engagement in vaccination efforts cannot be overstated. Community involvement in planning and implementing vaccination campaigns can enhance trust and increase participation rates. Research has shown that local knowledge and cultural practices can inform vaccination strategies, making them more acceptable to target populations (Njim et al., 2016). By adopting a sense of ownership among community members, public health authorities can improve vaccination uptake and ultimately achieve better health outcomes (Rast et al., 2010). This community-centered approach aligns with the findings of Parpia et al., who emphasize the importance of understanding local dynamics in the context of vaccination campaigns (Parpia et al., 2020).

The challenges associated with vaccine distribution and uptake are compounded by misinformation and vaccine hesitancy. Addressing these challenges requires a multifaceted approach that includes clear communication, education, and community engagement. Studies have demonstrated that misinformation can significantly impact vaccination rates, increasing susceptibility to outbreaks (Morrison et al., 2020). Therefore, public health campaigns must prioritize accurate information dissemination and actively counter misinformation to build public trust in vaccines (Nampanya et al., 2012). This proactive stance is essential for ensuring vaccination efforts are met with community support and participation.

Vaccine Hesitancy and Acceptance

Vaccine hesitancy regarding cholera vaccination is a multifaceted issue that significantly impacts public health outcomes, particularly in regions prone to cholera outbreaks. Vaccine hesitancy is often characterized by a reluctance or refusal to vaccinate despite the availability of vaccination services. This phenomenon can be attributed to various factors, including misinformation, distrust in healthcare systems, cultural beliefs, and fears regarding potential side effects. For instance, Merten et al. (2013) highlighted that local perceptions of cholera and anticipated vaccine acceptance are influenced by knowledge gaps regarding the disease, leading to hesitancy in accepting OCVs. Additionally, cultural beliefs, such as the association of illness with witchcraft or taboos, can further complicate vaccine acceptance. However, Merten et al. (2013) found that these beliefs were not significantly associated with OCV acceptability in their study. Table 5 shows the factors influencing vaccine hesitancy and acceptance.

Socioeconomic factors also play a crucial role in vaccine hesitancy. Individuals from lower socioeconomic backgrounds may face barriers to accessing healthcare services, which can deter them from seeking vaccination. Sundaram et al. (2015) found that a lack of education was significantly associated with non-acceptance of OCVs, suggesting that educational initiatives are vital for improving vaccine uptake. Furthermore, previous negative experiences with medical interventions can create a lasting distrust in healthcare systems, leading to reluctance to accept vaccines. This distrust is often exacerbated in communities where healthcare infrastructure is weak, as Burnett et al. (2016) noted that the effectiveness of prior health campaigns influenced knowledge and attitudes toward cholera vaccination.

The role of community engagement in addressing vaccine hesitancy cannot be overstated. Effective community engagement strategies can help mitigate concerns and misinformation surrounding cholera vaccines through education and dialogue. For example, Scheffold et al. (2012) emphasized the importance of culturally sensitive approaches in vaccination campaigns, which can enhance community trust and acceptance of OCVs. Engaging local leaders and influencers in the planning and implementing vaccination campaigns can further bolster vaccine acceptance. This is particularly important in regions where traditional beliefs and practices are deeply rooted, as local leaders can serve as trusted sources of information (Scheffold et al., 2012).

Moreover, community participation in vaccination campaigns ensures that strategies are relevant and tailored to the population's specific needs. Kirpich et al. (2017) demonstrated that community involvement in cholera vaccination efforts in Haiti led to a high acceptance rate, with over 90% of participants receiving both vaccine doses. This highlights the effectiveness of participatory approaches in increasing vaccine uptake. Additionally, the involvement of community members in the planning stages can help identify potential barriers to vaccination and develop targeted interventions to address these challenges (Sundaram et al., 2012).

Educational campaigns are essential for improving public knowledge about cholera and the benefits of vaccination. Studies have shown that increased awareness of cholera transmission pathways and symptoms significantly influences vaccine acceptability (Merten et al., 2013). For instance, in Zanzibar, individuals unaware of cholera's infectious pathways were less likely to accept the OCV during mass vaccination campaigns (Scheffold et al., 2012). Therefore, comprehensive educational initiatives that inform communities about cholera and the importance of vaccination are crucial for overcoming hesitancy. Furthermore, the timing and delivery of vaccination campaigns can impact public perception and acceptance. For example, the success of cholera vaccination campaigns in Haiti was attributed to the strategic timing of the campaigns, which coincided with periods of heightened cholera risk (Chao et al., 2011). This approach not only maximized vaccine coverage but also reinforced the urgency of vaccination in the minds of community members. Additionally, the use of single-dose OCVs has been proposed as a temporary measure to reduce cholera risk in the short term, which may further enhance community acceptance (Franke et al., 2018).

Trust in healthcare providers is another critical factor influencing vaccine acceptance. Individuals are more likely to accept vaccinations when they receive recommendations from trusted healthcare professionals. This underscores the need for healthcare providers to be well-informed and equipped to address concerns related to cholera vaccination (Stark et al., 2016). Moreover, establishing strong relationships between healthcare providers and community members can foster an environment of trust, which is essential for encouraging vaccine uptake. Despite the challenges posed by vaccine hesitancy, successful examples of cholera vaccination campaigns have effectively addressed public concerns. For instance, implementing community-based strategies in Uganda demonstrated the feasibility and effectiveness of OCV campaigns in response to cholera outbreaks (Bwire et al., 2020). These campaigns improved vaccine coverage and enhanced community engagement and trust in the healthcare system. Such examples highlight the potential for tailored interventions to overcome barriers to vaccine acceptance.

7. Conclusion

Vaccines are integral to the prevention and control of cholera, serving as a vital tool in long-term strategies aimed at mitigating the impact of this devastating disease. The current cholera vaccine landscape features a range of formulations, such as Dukoral®, Shanchol®, and Euvichol®, each with distinct advantages and limitations. To enhance vaccination efforts, it is essential to address the multifaceted challenges of vaccine distribution and access, which include public hesitancy, regulatory hurdles, and infrastructure limitations. A comprehensive approach that combines vaccination with improved sanitation practices, environmental monitoring, and equitable healthcare access is crucial for effectively reducing the global burden of cholera.

Emerging vaccine technologies, such as single-dose and thermostable vaccines, present promising prospects for cholera control, particularly in vulnerable populations and outbreak-prone regions. Ongoing research and innovative strategies are necessary to overcome existing barriers to vaccination, while community engagement and education will be vital in building trust and fostering vaccine acceptance. By prioritizing high-risk populations and integrating vaccination efforts with robust public health initiatives, including water, sanitation, and hygiene (WASH) programmes, we can enhance the effectiveness of cholera prevention efforts. The collaboration of public health authorities, communities, and researchers will be paramount in the pursuit of cholera elimination and protecting those most at risk.

References:

Alberti, K. P., King, L. A., Burny, M. E., Ilunga, B. K., & Grais, R. F. (2010). Reactive vaccination as an effective tool for measles outbreak control in measles mortality reduction settings, Democratic Republic of Congo, 2005–2006. International Health, 2(1), 65-68. https://doi.org/10.1016/j.inhe.2009.12.009

Ali, M., Debes, A. K., Luquero, F. J., Kim, D. R., Park, J. Y., Digilio, L., Manna, B., Kanungo, S., Dutta, S., Sur, D., et al. (2016). Potential for controlling cholera using a ring vaccination strategy: Re-analysis of data from a cluster-randomized clinical trial. PLOS Medicine, 13(9), e1002120. https://doi.org/10.1371/journal.pmed.1002120

Ali, M., Nelson, A., Luquero, F. J., Azman, A. S., Debes, A. K., M'bang'ombe, M. M., Seyama, L., Kachale, E., Zuze, K., Malichi, D., et al. (2017). Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: An observational cohort study. The Lancet Infectious Diseases, 17(5), 538-544. https://doi.org/10.1016/s1473-3099(16)30523-0

Alkahmous, M. A., Alyahya, A. Z. T., Almansour, A. N., Aldhfeeri, M. T., Alsanari, A. A., & Fagehi, S. E. Y. (2023). Assessment of vaccination rates and barriers in family medicine practices: A cross-sectional study. Middle East Journal of Family Medicine, 21(9), 25-32. https://doi.org/10.5742/mewfm.2023.95256192

Arteaga, M., Velasco, J., Rodriguez, S., Vidal, M., Arellano, C., Silva, F., Carreño, L. J., Vidal, R., & Montero, D. A. (2020). Genomic characterization of the non-O1/non-O139 Vibrio cholerae strain that caused a gastroenteritis outbreak in Santiago, Chile, 2018. Microbial Genomics, 6(3), e000340. https://doi.org/10.1101/835090

Azman, A. S., & Lessler, J. (2015). Reactive vaccination in the presence of disease hotspots. Proceedings of the Royal Society B: Biological Sciences, 282(1798), 20141341. https://doi.org/10.1098/rspb.2014.1341

Azman, A. S., Luquero, F. J., Rodrigues, A., Palma, P. P., Grais, R. F., Banga, C. N., Grenfell, B. T., & Lessler, J. (2012). Urban cholera transmission hotspots and their implications for reactive vaccination: Evidence from Bissau City, Guinea Bissau. PLOS Neglected Tropical Diseases, 6(11), e1901. https://doi.org/10.1371/journal.pntd.0001901

Bekolo, C. E., van Loenhout, J. A. F., Rodriguez-Llanes, J. M., Rumunu, J., Ramadan, O. P., & Guha-Sapir, D. (2016). A retrospective analysis of oral cholera vaccine use, disease severity, and deaths during an outbreak in South Sudan. Bulletin of the World Health Organization, 94(9), 667. https://doi.org/10.2471/blt.15.166892

Burnett, E., Dalipanda, T., Ogaoga, D., Gaiofa, J., Jilini, G., Halpin, A., Dietz, V., Date, K., Mintz, E., Hyde, T., et al. (2016). Knowledge, attitudes, and practices regarding diarrhea and cholera following an oral cholera vaccination campaign in the Solomon Islands. PLOS Neglected Tropical Diseases, 10(8), e0004937. https://doi.org/10.1371/journal.pntd.0004937

Bwire, G., Debes, A. K., Orach, C. G., Kagirita, A., Ram, M., Komakech, H., Voeglein, J. B., Buyinza, A. W., Obala, T., Brooks, W. A., & Sack, D. A. (2018). Environmental surveillance of Vibrio cholerae O1/O139 in Uganda's five African Great Lakes and other major surface water sources. Frontiers in Microbiology, 9, 1560. https://doi.org/10.3389/fmicb.2018.01560

Bwire, G., Kisakye, A., Amulen, E., Bwanika, J. B., Badebye, J., Aanyu, C., Nakirya, B. D., Okello, A., Okello, S. A., Bukenya, J. N., et al. (2022). Prevention of cholera and COVID-19 pandemics in Uganda: Understanding vaccine coverage survey plus. BMC Infectious Diseases. https://doi.org/10.21203/rs.3.rs-1997127/v1

Bwire, G., Roskosky, M., Ballard, A., Brooks, W. A., Okello, A., Rafael, F., Ampeire, I., Orach, C. G., & Sack, D. A. (2020). Use of surveys to evaluate an integrated oral cholera vaccine campaign in response to a cholera outbreak in Hoima District, Uganda. BMJ Open, 10(12), e038464. https://doi.org/10.1136/bmjopen-2020-038464

Bwire, G., Sack, D. A., Almeida, M., Li, S., Voeglein, J. B., Debes, A. K., Kagirita, A., Buyinza, A. W., Orach, C. G., & Stine, O. C. (2018). Molecular characterization of Vibrio cholerae responsible for cholera epidemics in Uganda by PCR, MLVA, and WGS. PLOS Neglected Tropical Diseases, 12(6), e0006492. https://doi.org/10.1371/journal.pntd.0006492

Chao, D. L., Halloran, M. E., & Longini Jr, I. M. (2011). Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proceedings of the National Academy of Sciences, 108(17), 7081-7085. https://doi.org/10.1073/pnas.1102149108

Charles, R. C., Hilaire, I. J., Mayo-Smith, L. M., Teng, J. E., Jerome, J. G., Franke, M. F., Saha, A., Yu, Y., Kováč, P., Calderwood, S. B., et al. (2014). Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti. PLOS Neglected Tropical Diseases, 8(5), e2828. https://doi.org/10.1371/journal.pntd.0002828

Dean, N. E., Gsell, P. S., Brookmeyer, R., De Gruttola, V., Donnelly, C. A., Halloran, M. E., Jasseh, M., Nason, M., Riveros, X., Watson, C. H., & others. (2019). Design of vaccine efficacy trials during public health emergencies. Science Translational Medicine, 11(499). https://doi.org/10.1126/scitranslmed.aat0360

Dimitrov, D. T., Troeger, C., Halloran, M. E., Longini, I. M., & Chao, D. L. (2014). Comparative effectiveness of different strategies of oral cholera vaccination in Bangladesh: A modeling study. PLoS Neglected Tropical Diseases, 8(12), e3343. https://doi.org/10.1371/journal.pntd.0003343

Duan, Y., Shi, J., Wang, Z., Zhou, S., Jin, Y., & Zheng, Z. J. (2021). Disparities in COVID-19 vaccination among low-, middle-, and high-income countries: The mediating role of vaccination policy. Vaccines, 9(8), 905. https://doi.org/10.3390/vaccines9080905

Escoffery, C., Ogutu, E. A., Sakas, Z., Hester, K. A., Ellis, A., Rodriguez, K., Jaishwal, C., Yang, C., Dixit, S., Bose, A., & others. (2023). Drivers of early childhood vaccination success in Nepal, Senegal, and Zambia: A multiple case study analysis using the consolidated framework for implementation research. Implementation Science Communications, 4(1), 109. https://doi.org/10.1101/2023.04.05.23288208

Falkard, B., Charles, R. C., Matias, W. R., Mayo-Smith, L. M., Jerome, J. G., Offord, E. S., Xu, P., Kováč, P., Ryan, E. T., Qadri, F., & others. (2019). Bivalent oral cholera vaccination induces a memory B cell response to the V. cholerae O1-polysaccharide antigen in Haitian adults. PLoS Neglected Tropical Diseases, 13(1), e0007057. https://doi.org/10.1371/journal.pntd.0007057

Faucher, B., Assab, R., Roux, J., Levy-Bruhl, D., Kiem, C. T., Cauchemez, S., Zanetti, L., Colizza, V., Boëlle, P. Y., & Poletto, C. (2021). Reactive vaccination of workplaces and schools against COVID-19. medRxiv. https://doi.org/10.1101/2021.07.26.21261133

Faucher, B., Assab, R., Roux, J., Levy-Bruhl, D., Tran Kiem, C., Cauchemez, S., Zanetti, L., Colizza, V., Boëlle, P. Y., & Poletto, C. (2022). Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19. Nature Communications, 13(1), 1414. https://doi.org/10.1038/s41467-022-29015-y

Forman, R., Shah, S., Jeurissen, P., Jit, M., & Mossialos, E. (2021). COVID-19 vaccine challenges: What have we learned so far and what remains to be done? Health Policy, 125(5), 553–567. https://doi.org/10.1016/j.healthpol.2021.03.013

Franke, M. F., Ternier, R., Jerome, J. G., Matias, W. R., Harris, J. B., & Ivers, L. C. (2018). Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: An extended case-control study. The Lancet Global Health, 6(9), e1028–e1035. https://doi.org/10.1016/S2214-109X(18)30284-5

Gachohi, J., Bett, B., Otieno, F., Mogoa, E., Njoki, P., Muturi, M., Mwatondo, A., Osoro, E., Ngere, I., Dawa, J., & others. (2022). Anthrax hotspot mapping in Kenya support establishing a sustainable two-phase elimination program targeting less than 6% of the country landmass. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-24000-3

Hall, V., Banerjee, E., Kenyon, C., Strain, A., Griffith, J., Como‐Sabetti, K., Heath, J., Bahta, L., Martin, K., McMahon, M., & others. (2017). Measles outbreak — Minnesota April–May 2017. MMWR Morbidity and Mortality Weekly Report, 66(27), 713–717. https://doi.org/10.15585/mmwr.mm6627a1

Harris, J. B. (2018). Cholera: Immunity and prospects in vaccine development. The Journal of Infectious Diseases, 218(Suppl 3), S141–S146. https://doi.org/10.1093/infdis/jiy414

El Hayek, P., Boueri, M., Nasr, L., Aoun, C., Sayad, E., & Jallad, K. (2023). Cholera infection risks and cholera vaccine safety in pregnancy. Infectious Diseases in Obstetrics and Gynecology, 2023, 1–8. https://doi.org/10.1155/2023/4563797

Hill, M., & Okugo, G. (2014). Emergency medicine physician attitudes toward HPV vaccine uptake in an emergency department setting. Human Vaccines & Immunotherapeutics, 10(9), 2551–2556. https://doi.org/10.4161/21645515.2014.970933

Hsiao, A., Desai, S. N., Mogasale, V., Excler, J. L., & Digilio, L. (2017). Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings. Bulletin of the World Health Organization, 95(4), 303–312. https://doi.org/10.2471/blt.16.175166

Ilboudo, P. G., & Le Gargasson, J. B. (2017). Delivery cost analysis of a reactive mass cholera vaccination campaign: A case study of Shanchol™ vaccine use in Lake Chilwa, Malawi. BMC Infectious Diseases, 17(1). https://doi.org/10.1186/s12879-017-2885-8

Ilboudo, P. G., Mengel, M. A., Gessner, B. D., Ngwira, B., Cavailler, P., & Le Gargasson, J. B. (2021). Cost-effectiveness of a reactive oral cholera immunization campaign using Shanchol™ in Malawi. Cost Effectiveness and Resource Allocation, 19(1). https://doi.org/10.1186/s12962-021-00270-y

Islam, K., Hossain, M., Kelly, M., Mayo Smith, L. M., Charles, R. C., Bhuiyan, T. R., Kováč, P., Xu, P., LaRocque, R. C., Calderwood, S. B., & Others. (2018). Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers. PLoS Neglected Tropical Diseases, 12(4), e0006376. https://doi.org/10.1371/journal.pntd.0006376

Ivers, L., Charles, R., Hilaire, I., Mayo-Smith, L., Teng, J., Jerome, J., & Harris, J. (2015). Immunogenicity of the bivalent oral cholera vaccine Shanchol in Haitian adults with HIV infection. The Journal of Infectious Diseases, 212(5), 779-783. https://doi.org/10.1093/infdis/jiv108

Ivers, L. C., Hilaire, I. J., Teng, J. E., Almazor, C. P., Jerome, J. G., Ternier, R., Boncy, J., Buteau, J., Murray, M. B., Harris, J. B., & Franke, M. F. (2015). Effectiveness of reactive oral cholera vaccination in rural Haiti: A case-control study and bias-indicator analysis. The Lancet Global Health, 3(3), e162-e168. https://doi.org/10.1016/s2214-109x(14)70368-7

Ivers, L. C., Teng, J. E., Lascher, J., Raymond, M., Weigel, J., Victor, N., Jerome, J. G., Hilaire, I. J., Almazor, C. P., & Ternier, R. (2013). Use of oral cholera vaccine in Haiti: A rural demonstration project. American Journal of Tropical Medicine and Hygiene, 89(4), 617-624. https://doi.org/10.4269/ajtmh.13-0183

Izzati, A. N., Indarwati, R., Makhfudli, M., Utomo, B., Has, E. M. M., Arief, Y. S., & Arifin, H. (2021). Pro- and anti-vaccination among mothers in deciding children’s immunization: A qualitative study. Open Access Macedonian Journal of Medical Sciences, 9(B), 385-391. https://doi.org/10.3889/oamjms.2021.6113

Kanungo, S., Desai, S. N., Nandy, R. K., Bhattacharya, M. K., Kim, D. R., Sinha, A., Mahapatra, T., Yang, J. S., Lopez, A. L., Manna, B., & Others. (2015). Flexibility of oral cholera vaccine dosing—a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone. PLoS Neglected Tropical Diseases, 9(3), e0003574. https://doi.org/10.1371/journal.pntd.0003574

Kar, S. K., Pach, A., Sah, B., Kerketta, A. S., Patnaik, B., Mogasale, V., Kim, Y. H., Rath, S. B., Shin, S., Khuntia, H. K., & Others. (2014). Uptake during an oral cholera vaccine pilot demonstration program, Odisha, India. Human Vaccines & Immunotherapeutics, 10(10), 2834-2842. https://doi.org/10.4161/21645515.2014.971655

Kar, S. K., Sah, B., Patnaik, B., Kim, Y. H., Kerketta, A. S., Shin, S., Rath, S. B., Ali, M., Mogasale, V., Khuntia, H. K., & Others. (2014). Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: The Odisha model. PLoS Neglected Tropical Diseases, 8(2), e2629. https://doi.org/10.1371/journal.pntd.0002629

Khan, A. I., Levin, A., Chao, D. L., DeRoeck, D., Dimitrov, D. T., Khan, J. A., Islam, M. S., Ali, M., Islam, M. T., Sarker, A. R., & Others. (2018). The impact and cost-effectiveness of controlling cholera through the use of oral cholera vaccines in urban Bangladesh: A disease modeling and economic analysis. PLoS Neglected Tropical Diseases, 12(10), e0006652. https://doi.org/10.1371/journal.pntd.0006652

Khuntia, H. K., Ramamurthy, T., Bal, M., Pati, S., & Ranjit, M. (2021). Decades of cholera in Odisha, India (1993–2015): Lessons learned and the ways forward. Epidemiology and Infection, 149. https://doi.org/10.1017/s0950268821001266

Kirpich, A., Weppelmann, T. A., Yang, Y., Morris, J. G., Jr., & Longini, I. M., Jr. (2017). Controlling cholera in the Ouest Department of Haiti using oral vaccines. PLoS Neglected Tropical Diseases, 11(4), e0005482. https://doi.org/10.1371/journal.pntd.0005482

Kundrick, A., Huang, Z., Carran, S., Kagoli, M., Grais, R. F., Hurtado, N., & Ferrari, M. (2018). Sub-national variation in measles vaccine coverage and outbreak risk: A case study from a 2010 outbreak in Malawi. BMC Public Health, 18(1). https://doi.org/10.1186/s12889-018-5628-x

Luquero, F. J., Grout, L., Ciglenecki, I., Sakoba, K., Traore, B., Heile, M., Diallo, A. A., Itama, C., Page, A. L., Quilici, M. L., & Others. (2014). Use of Vibrio cholerae vaccine in an outbreak in Guinea. New England Journal of Medicine, 370(22), 2111-2120. https://doi.org/10.1056/nejmoa1312680

Mahalanabis, D., Lopez, A. L., Sur, D., Deen, J., Manna, B., Kanungo, S., Von Seidlein, L., Carbis, R., Han, S. H., Shin, S. H., & Others. (2008). A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One, 3(6), e2323. https://doi.org/10.1371/journal.pone.0002323

Martin, S., Lopez, A. L., Bellos, A., Deen, J., Ali, M., Alberti, K., Anh, D. D., Costa, A., Grais, R. F., Legros, D., & Others. (2014). Post-licensure deployment of oral cholera vaccines: A systematic review. Bulletin of the World Health Organization, 92(12), 881-893. https://doi.org/10.2471/blt.14.139949

Martinez-Pino, I., Luquero, F. J., Sakoba, K., Sylla, S., Haile, M., Grais, R. F., Ciglenecki, I., Quilici, M. L., & Page, A. L. (2013). Use of a cholera rapid diagnostic test during a mass vaccination campaign in response to an epidemic in Guinea, 2012. PLoS Neglected Tropical Diseases, 7(8), e2366. https://doi.org/10.1371/journal.pntd.0002366

Merler, S., Ajelli, M., Fumanelli, L., Parlamento, S., Pastore y Piontti, A., Dean, N. E., Putoto, G., Carraro, D., Longini, I. M., Jr., Halloran, M. E., & Vespignani, A. (2016). Containing Ebola at the source with ring vaccination. PLoS Neglected Tropical Diseases, 10(11), e0005093. https://doi.org/10.1371/journal.pntd.0005093

Merten, S., Schaetti, C., Manianga, C., Lapika, B., Chaignat, C. L., Hutubessy, R., & Weiss, M. G. (2013). Local perceptions of cholera and anticipated vaccine acceptance in Katanga Province, Democratic Republic of Congo. BMC Public Health, 13(1). https://doi.org/10.1186/1471-2458-13-60

Morales, K. F., Brown, D. W., Dumolard, L., Steulet, C., Vilajeliu, A., Alvarez, A. M. R., Moen, A., Friede, M., & Lambach, P. (2021). Seasonal influenza vaccination policies in the 194 WHO member states: The evolution of global influenza pandemic preparedness and the challenge of sustaining equitable vaccine access. Vaccine X, 8, 100097. https://doi.org/10.1016/j.jvacx.2021.100097

Morrison, M., Castro, L. A., & Meyers, L. A. (2020). Conscientious vaccination exemptions in kindergarten to eighth-grade children across Texas schools from 2012 to 2018: A regression analysis. PLOS Medicine, 17(3), e1003049. https://doi.org/10.1371/journal.pmed.1003049

Mukandavire, Z., Manangazira, P., Nyabadza, F., Cuadros, D. F., Musuka, G., & Morris Jr, J. G. (2020). Stemming cholera tides in Zimbabwe through mass vaccination. International Journal of Infectious Diseases, 96, 222-227. https://doi.org/10.1016/j.ijid.2020.03.077

Mukandavire, Z., Smith, D. L., & Morris Jr, J. G. (2013). Cholera in Haiti: Reproductive numbers and vaccination coverage estimates. Scientific Reports, 3(1). https://doi.org/10.1038/srep00997

Nampanya, S., Richards, J., Khounsy, S., Inthavong, P., Yang, M., Rast, L., & Windsor, P. A. (2012). Investigation of foot and mouth disease hotspots in northern Lao PDR. Transboundary and Emerging Diseases, 60(4), 315-329. https://doi.org/10.1111/j.1865-1682.2012.01350.x

Njim, T., Agyingi, K., Aminde, L. N., & Atunji, E. F. (2016). Trend in mortality from a recent measles outbreak in Cameroon: A retrospective analysis of 223 measles cases in the Benakuma health district. Pan African Medical Journal, 23. https://doi.org/10.11604/pamj.2016.23.135.8630

Nkwenkeu, S. F., Jalloh, M. F., Walldorf, J. A., Zoma, R. L., Tarbangdo, F., Fall, S., Hien, S., Combassere, R., Ky, C., Kambou, L., et al. (2020). Health workers’ perceptions and challenges in implementing meningococcal serogroup A conjugate vaccine in the routine childhood immunization schedule in Burkina Faso. BMC Public Health, 20(1). https://doi.org/10.1186/s12889-020-8347-z

Parker, L. A., Rumunu, J., Jamet, C., Kenyi, Y., Lino, R. L., Wamala, J. F., Mpairwe, A. M., Muller, V., Llosa, A. E., Uzzeni, F., et al. (2017). Neighborhood-targeted and case-triggered use of a single dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage. PLOS Neglected Tropical Diseases, 11(6), e0005652. https://doi.org/10.1371/journal.pntd.0005652

Parpia, A. S., Skrip, L. A., Nsoesie, E. O., Ngwa, M. C., Abah, A. S. A., Galvani, A. P., & Ndeffo-Mbah, M. L. (2020). Spatio-temporal dynamics of measles outbreaks in Cameroon. Annals of Epidemiology, 42, 64-72.e3. https://doi.org/10.1016/j.annepidem.2019.10.007

Peak, C. M., Reilly, A. L., Azman, A. S., & Buckee, C. O. (2018). Prolonging herd immunity to cholera via vaccination: Accounting for human mobility and waning vaccine effects. PLOS Neglected Tropical Diseases, 12(2), e0006257. https://doi.org/10.1371/journal.pntd.0006257

Poncin, M., Zulu, G., Voute, C., Ferreras, E., Muleya, C. M., Malama, K., Pezzoli, L., Mufunda, J., Robert, H., Uzzeni, F., et al. (2017). Implementation research: Reactive mass vaccination with single-dose oral cholera vaccine, Zambia. Bulletin of the World Health Organization, 96(2), 86-93. https://doi.org/10.2471/blt.16.189241

Qadri, F., Ali, M., Lynch, J., Chowdhury, F., Khan, A. I., Wierzba, T. F., Excler, J. L., Saha, A., Islam, M. T., Begum, Y. A., et al. (2018). Efficacy of a single-dose regimen of inactivated whole-cell oral cholera vaccine: Results from 2 years of follow-up of a randomized trial. The Lancet Infectious Diseases, 18(6), 666-674. https://doi.org/10.1016/s1473-3099(18)30108-7

Qadri, F., Wierzba, T. F., Ali, M., Chowdhury, F., Khan, A. I., Saha, A., Khan, I. A., Asaduzzaman, M., Akter, A., Khan, A., et al. (2016). Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. New England Journal of Medicine, 374(18), 1723-1732. https://doi.org/10.1056/nejmoa1510330

Rast, L., Windsor, P. A., & Khounsy, S. (2010). Limiting the impacts of foot and mouth disease in large ruminants in northern Lao People’s Democratic Republic by vaccination: A case study. Transboundary and Emerging Diseases, 57(3), 147-153. https://doi.org/10.1111/j.1865-1682.2010.01099.x

Roskosky, M., Ali, M., Upreti, S. R., & Sack, D. (2020). Spatial clustering of cholera cases in the Kathmandu Valley: Implications for a ring vaccination strategy. International Health, 13(2), 170-177. https://doi.org/10.1093/inthealth/ihaa042

Sarker, A. R., Islam, Z., Khan, I. A., Saha, A., Chowdhury, F., Khan, A. I., Cravioto, A., Clemens, J. D., Qadri, F., & Khan, J. A. (2015). Estimating the cost of cholera-vaccine delivery from the societal point of view: A case of introduction of cholera vaccine in Bangladesh. Vaccine, 33(38), 4916-4921. https://doi.org/10.1016/j.vaccine.2015.07.042

Sayeed, M. A., Bufano, M. K., Xu, P., Eckhoff, G., Charles, R. C., Alam, M. M., Sultana, T., Rashu, M. R., Berger, A., Gonzalez-Escobedo, G., et al. (2015). A cholera conjugate vaccine containing O-specific polysaccharide (OSP) of V. cholerae O1 Inaba and recombinant fragment of tetanus toxin heavy chain (OSP: rTTHc) induces serum, memory and lamina proprial responses against OSP and is protective in mice. PLOS Neglected Tropical Diseases, 9(7), e0003881. https://doi.org/10.1371/journal.pntd.0003881

Schaetti, C., Ali, S. M., Chaignat, C. L., Khatib, A. M., Hutubessy, R., & Weiss, M. G. (2012). Improving community coverage of oral cholera mass vaccination campaigns: Lessons learned in Zanzibar. PLOS ONE, 7(7), e41527. https://doi.org/10.1371/journal.pone.0041527

Schaetti, C., Ali, S. M., Hutubessy, R., Khatib, A. M., Chaignat, C. L., & Weiss, M. G. (2012). Social and cultural determinants of oral cholera vaccine uptake in Zanzibar. Human Vaccines & Immunotherapeutics, 8(9), 1223–1229. https://doi.org/10.4161/hv.20901

Shaikh, B. T., Haq, Z. U., Tran, N., & Hafeez, A. (2018). Health system barriers and levers in implementation of the expanded program on immunization (EPI) in Pakistan: An evidence-informed situation analysis. Public Health Reviews, 39(1), 1–9. https://doi.org/10.1186/s40985-018-0103-x

Sow, S. O., Tapia, M. D., Chen, W. H., Haidara, F. C., Kotloff, K. L., Pasetti, M. F., Blackwelder, W. C., Traoré, A., Tamboura, B., Doumbia, M., et al. (2017). Randomized, placebo-controlled, double-blind phase 2 trial comparing the reactogenicity and immunogenicity of a single standard dose to those of a high dose of CVD 103-HgR live attenuated oral cholera vaccine, with Shanchol inactivated oral vaccine as an open-label immunologic comparator. Clinical and Vaccine Immunology, 24(12). https://doi.org/10.1128/cvi.00265-17

Stark, L. M., Power, M. L., Turrentine, M., Samelson, R., Siddiqui, M. M., Paglia, M. J., Strassberg, E. R., Kelly, E., Murtough, K. L., & Schulkin, J. (2016). Influenza vaccination among pregnant women: Patient beliefs and medical provider practices. Infectious Diseases in Obstetrics and Gynecology, 2016, 1–8. https://doi.org/10.1155/2016/3281975

Sundaram, N., Schaetti, C., Chaignat, C. L., Hutubessy, R., Nyambedha, E. O., Mbonga, L. A., & Weiss, M. G. (2012). Socio-cultural determinants of anticipated acceptance of an oral cholera vaccine in Western Kenya. Epidemiology and Infection, 141(3), 639–650. https://doi.org/10.1017/s0950268812000829

Sur, D., Kanungo, S., Sah, B., Manna, B., Ali, M., Paisley, A. M., Niyogi, S. K., Park, J. K., Sarkar, B., Puri, M. K., et al. (2011). Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: Results from 3 years of follow-up of a randomized, controlled trial. PLOS Neglected Tropical Diseases, 5(10), e1289. https://doi.org/10.1371/journal.pntd.0001289

Troeger, C., Sack, D. A., & Chao, D. L. (2014). Evaluation of targeted mass cholera vaccination strategies in Bangladesh: A demonstration of a new cost-effectiveness calculator. American Journal of Tropical Medicine and Hygiene, 91(6), 1181–1189. https://doi.org/10.4269/ajtmh.14-0159

Yazdani, A. T., Muhammad, A., Nisar, M. I., Khan, U., & Shafiq, Y. (2021). Unveiling and addressing implementation barriers to routine immunization in the peri-urban slums of Karachi, Pakistan: A mixed-methods study. Health Research Policy and Systems, 19(1), 1–9. https://doi.org/10.21203/rs.3.rs-204016/v1

ARTICLE INFO	ABSTRACT
*Article No.:* 102024146 *Type: Research* *Full Text: PDF, PHP, HTML, EPUB, MP3* *DOI:10.15580/gjbhs.2024.1.102024146*	Cholera poses a significant public health challenge, particularly in regions prone to outbreaks. Vaccination plays a critical role in preventing cholera, offering a powerful strategy to mitigate its impact. The paper focuses on the progress and efficacy of cholera vaccine development. The paper found that the cholera vaccine landscape features diverse formulations, including Dukoral®, Shanchol®, and Euvichol®, each having distinct advantages and limitations. While substantial progress has been made in vaccine development, ongoing research is essential to address existing barriers such as distribution challenges, public hesitancy, and limited access to healthcare. Therefore, effective public health strategies should prioritize high-risk populations and integrate vaccination efforts with improved sanitation and water, sanitation, and hygiene (WASH) programmes. Additionally, fostering community engagement through education and local leadership is crucial to overcoming vaccine hesitancy, which is influenced by misinformation and cultural beliefs. Collaboration among public health authorities, researchers, and communities is vital for enhancing vaccine uptake and achieving cholera elimination goals. As challenges evolve, the adaptability of vaccination strategies will be paramount in safeguarding community health and preventing future outbreaks.
*Accepted:* 05/11/2024 *Published:* 19/11/2024
Corresponding Author Sylvester Chibueze Izah* *E-mail:* chivestizah@gmail.com
*Keywords: Cholera, Vaccine Development, Public Health, Vaccine Efficacy, Sanitation, Vaccine Hesitancy, Outbreak Prevention*

Period	Vaccine Type	Key Developments	Challenges
Late 19th Century	Injectable (Killed Vaccine)	Waldemar Haffkine developed the first cholera vaccine using heat-killed Vibrio cholera	Limited effectiveness, short-lived immunity, adverse reactions, and difficulties in mass administration
1960s-1970s	First-Generation Oral Cholera Vaccines (OCVs)	Developed killed whole-cell and live-attenuated OCVs	Short-lived immunity, multiple doses required, safety concerns for live vaccines
1990s	Second-Generation Oral Vaccines	Introduction of Dukoral and WC-rBS, combining killed bacteria and cholera toxin components	Required two doses, initially aimed at travelers, complex administration with buffer solution
2011-Present	New-Generation Oral Cholera Vaccines	Shanchol and Euvichol introduced more accessible mass vaccination in endemic areas.	Cost and accessibility challenges are reduced, but logistics and cold chain requirements remain.

Vaccine	Type	Efficacy & Duration	Safety Profile
Dukoral®	Killed whole-cell, oral	60-85% protection for 2-3 years	Mild side effects: gastrointestinal discomfort, nausea
Shanchol®	Killed whole-cell, oral	~65% protection for up to 5 years	Well tolerated; mild side effects: diarrhea, abdominal pain
Euvichol®	Killed whole-cell, oral	~65% protection for 3-5 years	Generally well tolerated; mild side effects: nausea, vomiting

Strategy	Description	Benefits	Key Components
Targeting high-risk populations and outbreak hotspots	Focus on vaccinating high-risk groups (healthcare workers, elderly, individuals with pre-existing conditions). Utilize epidemiological data to identify outbreak hotspots.	Contain and prevent disease spread; protect vulnerable populations.	Identifying high-risk groups, epidemiological data analysis, and targeted outreach.
Integration with water, sanitation, and hygiene programmes and surveillance	Combine vaccination efforts with Water, Sanitation, and Hygiene programmes. Establish surveillance systems to monitor coverage and outbreaks.	It enhances public health, reduces disease transmission, and supports vaccine efficacy.	Water, Sanitation, and Hygiene programme implementation, robust surveillance systems, timely response mechanisms.